Head to head
Lanifibranor against Pioglitazone
Both act on PPAR receptors and both have been tested in metabolic liver disease. Pioglitazone is approved for diabetes, cheap, and carries a boxed warning for heart failure; lanifibranor is investigational and hits all three PPAR subtypes rather than one.
Column A
LanifibranorLanifibranor, pan-PPAR agonist
An oral pan-PPAR agonist for MASH whose 1,000-patient Phase 3 (NATiV3) completed its last patient visit in September 2026, with results due by year end.
Column B
PioglitazonePioglitazone (Actos), thiazolidinedione PPAR-gamma agonist
An approved diabetes drug with real cardiovascular outcome data in people, and the only compound in the 2026 mouse cohort that shortened female lifespan in the analysis that survived removing an outlier site.
Side by side, on the facts we can check
| Attribute | Lanifibranor | Pioglitazone |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational; Phase 3 completed dosing | FDA-approved as Actos for type 2 diabetes. Carries a boxed warning for congestive heart failure. Not approved for any ageing or longevity indication. |
| Half-life | Once-daily oral dosing | Three to seven hours for the parent compound, with active metabolites extending to roughly 16 to 24 hours, which supports once-daily dosing. |
| Molecular weight | 434.9 Da | 356.4 Da. A small molecule, not a peptide. |
| Mechanism | Pan-PPAR agonism improving hepatic lipid metabolism, reducing inflammation and stellate-cell activation. | An agonist at peroxisome proliferator-activated receptor gamma, a nuclear receptor expressed most highly in adipose tissue. Activating it drives differentiation of new small insulin-sensitive adipocytes, redistributes lipid away from liver and muscle, and lowers circulating free fatty acids, which is how it improves whole-body insulin sensitivity. The same receptor activity drives sodium retention in the kidney, which is the mechanism behind the oedema and heart failure risk, and shifts marrow stem cells toward fat rather than bone, which is the plausible route to the fracture signal. |
| Human studies cited | 2 | 0 |
| Legal status, US | Investigational, not approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Lanifibranor and Pioglitazone?
Lanifibranor: An oral pan-PPAR agonist for MASH whose 1,000-patient Phase 3 (NATiV3) completed its last patient visit in September 2026, with results due by year end. Pioglitazone: An approved diabetes drug with real cardiovascular outcome data in people, and the only compound in the 2026 mouse cohort that shortened female lifespan in the analysis that survived removing an outlier site.
Which has stronger research evidence, Lanifibranor or Pioglitazone?
This database does not grade compounds. It counts what was run in people: 2 of the 2 studies cited on the Lanifibranor profile were human work, against 0 of 1 for Pioglitazone. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Lanifibranor and Pioglitazone FDA-approved?
Lanifibranor: Investigational; Phase 3 completed dosing. Pioglitazone: FDA-approved as Actos for type 2 diabetes. Carries a boxed warning for congestive heart failure. Not approved for any ageing or longevity indication..
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.